{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:18:07Z","timestamp":1793114287518,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Medication for opioid use disorder (MOUD) is the gold standard treatment for opioid use disorder. Traditionally, \u201csuccess\u201d in MOUD treatment is measured in terms of program retention, adherence to MOUD, and abstinence from opioid and other drug use. While clinically meaningful, these metrics may overlook other aspects of the lives of people with opioid use disorder (OUD) and surprisingly do not reflect the diagnostic criteria for OUD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Authors identified items for a pilesorting task to identify participant-driven measures of MOUD treatment success through semi-structured interviews. Interviews were transcribed verbatim and coded in Nvivo using directed and conventional content analysis to identify measures related to treatment success and quality of life goals. Participants of a low-threshold MOUD program were recruited and asked to rank identified measures in order of importance to their own lives. Multidimensional scaling (MDS) compared the similarity of items while non-metric MDS in R specified a two-dimensional solution. Descriptive statistics of participant demographics were generated in SPSS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen semi-structured interviews were conducted between June and August 2020 in Philadelphia, PA, USA, and 23 measures were identified for a pilesorting activity. These were combined with 6 traditional measures for a total list of 29 items. Data from 28 people were included in pilesorting analysis. Participants identified a combination of traditional and stakeholder-defined recovery goals as highly important, however, we identified discrepancies between the most frequent and highest ranked items within the importance categories. Measures of success for participants in MOUD programs were complex, multi-dimensional, and varied by the individual. However, some key domains such as emotional well-being, decreased drug use, and attendance to basic functioning may have universal importance. The following clusters of importance were identified: emotional well-being, decreased drug use, and human functioning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Outcomes from this research have practical applications for those working to provide services in MOUD programs. Programs can use aspects of these domains to both provide patient-centered care and to evaluate success. Specifics from the pilesorting results may also inform approaches to collaborative goal setting during treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13011-022-00510-1","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T05:02:47Z","timestamp":1673672567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program"],"prefix":"10.1186","volume":"18","author":[{"given":"Megan K.","family":"Reed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ciocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Hass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery Lin","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara C.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"issue":"6","key":"510_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/GERONT\/31.6.726","volume":"31","author":"SM Albert","year":"1991","unstructured":"Albert SM. Cognition of caregiving tasks: multidimensional scaling of the caregiver task domain. Gerontologist. 1991;31(6):726\u201334. https:\/\/doi.org\/10.1093\/GERONT\/31.6.726.","journal-title":"Gerontologist"},{"key":"510_CR2","unstructured":"American Psychiatric Association. Opioid Use Disorder. https:\/\/www.psychiatry.org\/patientsfamilies\/addiction\/opioid-use-disorder. Published November 2018. Accessed 24 Feb 2022."},{"key":"510_CR3","doi-asserted-by":"publisher","unstructured":"Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within prevention point Philadelphia, an urban syringe exchange program.\u00a0Subst Abus.\u00a02018;39(2):167\u201372. https:\/\/doi.org\/10.1080\/08897077.2018.1443541.","DOI":"10.1080\/08897077.2018.1443541"},{"issue":"1","key":"510_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M18-3457\/SUPPL_FILE\/M18-3457_SUPPLEMENT.PDF","volume":"171","author":"T Beetham","year":"2019","unstructured":"Beetham T, Saloner B, Wakeman SE, Gaye M, Barnett ML. Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med. 2019;171(1):1\u20139. https:\/\/doi.org\/10.7326\/M18-3457\/SUPPL_FILE\/M18-3457_SUPPLEMENT.PDF.","journal-title":"Ann Intern Med"},{"key":"510_CR5","doi-asserted-by":"publisher","unstructured":"Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. A literature review examining primary outcomes of medication treatment studies for opioid use disorder: What outcome should be used to measure opioid treatment success? Am J Addict. 2020;29(4):249\u201367. https:\/\/doi.org\/10.1111\/AJAD.13051.","DOI":"10.1111\/AJAD.13051"},{"key":"510_CR6","first-page":"1","volume-title":"The Ethnographier\u2019s toolkit","author":"SP Borgatti","year":"1998","unstructured":"Borgatti SP. Elicitation techniques for cultural domain analysis. In: Schensul J, LeCompte M, editors. The Ethnographier\u2019s toolkit. 3rd ed. Walnut Creek: Altmira Press; 1998. p. 1\u201326.","edition":"3"},{"key":"510_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/J.JSAT.2017.01.019","volume":"76","author":"JW Bray","year":"2017","unstructured":"Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, et al. Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abuse Treat. 2017;76:88. https:\/\/doi.org\/10.1016\/J.JSAT.2017.01.019.","journal-title":"J Subst Abuse Treat"},{"key":"510_CR8","unstructured":"Centers for Disease Control and Prevention. U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020 -\nBut Are Still Up 15%. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm. Published May 11, 2022. Accessed 4 July 2022."},{"key":"510_CR9","doi-asserted-by":"publisher","unstructured":"Dale-Perera A, Alam F, Barker P. Opioid-dependence treatment in the era of recovery: Insights from a UK survey of physicians, patients and out-of-treatment opioid users. J Subst Use. 2015;20(5):354\u201362. https:\/\/doi.org\/10.3109\/14659891.2014.923532.","DOI":"10.3109\/14659891.2014.923532"},{"issue":"1","key":"510_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/S11205-008-9315-7\/TABLES\/2","volume":"90","author":"J De Maeyer","year":"2009","unstructured":"De Maeyer J, Vanderplasschen W, Broekaert E. Exploratory study on drug users\u2019 perspectives on quality of life: more than health-related quality of life? Soc Indic Res. 2009;90(1):107\u201326. https:\/\/doi.org\/10.1007\/S11205-008-9315-7\/TABLES\/2.","journal-title":"Soc Indic Res"},{"issue":"5","key":"510_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/J.DRUGPO.2010.01.010","volume":"21","author":"J De Maeyer","year":"2010","unstructured":"De Maeyer J, Vanderplasschen W, Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int J Drug Policy. 2010;21(5):364\u201380. https:\/\/doi.org\/10.1016\/J.DRUGPO.2010.01.010.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"510_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11920-020-01149-0\/TABLES\/3","volume":"22","author":"JH Donroe","year":"2020","unstructured":"Donroe JH, Bhatraju EP, Tsui JI, Edelman EJ. Identification and Management of Opioid use Disorder in primary care: an update. Curr Psychiatry Rep. 2020;22(5):1\u201311. https:\/\/doi.org\/10.1007\/S11920-020-01149-0\/TABLES\/3.","journal-title":"Curr Psychiatry Rep"},{"key":"510_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/J.JSAT.2020.108093","volume":"117","author":"C Drake","year":"2020","unstructured":"Drake C, Donohue JM, Nagy D, Mair C, Kraemer KL, Wallace DJ. Geographic access to buprenorphine prescribers for patients who use public transit. J Subst Abuse Treat. 2020;117:108093. https:\/\/doi.org\/10.1016\/J.JSAT.2020.108093.","journal-title":"J Subst Abuse Treat"},{"key":"510_CR14","doi-asserted-by":"publisher","unstructured":"Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022;231. https:\/\/doi.org\/10.1016\/J.DRUGALCDEP.2021.109254.","DOI":"10.1016\/J.DRUGALCDEP.2021.109254"},{"key":"510_CR15","doi-asserted-by":"publisher","unstructured":"Fanucchi L, Springer SA, Korthuis PT. Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV\/AIDS Rep. 2019;16(1). https:\/\/doi.org\/10.1007\/S11904-019-00436-7.","DOI":"10.1007\/S11904-019-00436-7"},{"key":"510_CR16","doi-asserted-by":"publisher","unstructured":"Fischer JA, Conrad S, Clavarino AM, Kemp R, Najman JM. Quality of life of people who inject drugs: Characteristics and comparisons with other population samples. Qual Life Res. 2013;22(8):2113\u201321. https:\/\/doi.org\/10.1007\/S11136-013-0350-8\/TABLES\/4.","DOI":"10.1007\/S11136-013-0350-8\/TABLES\/4"},{"key":"510_CR17","doi-asserted-by":"publisher","unstructured":"Gelpi-Acosta C. Challenging biopower: \u201cliquid cuffs\u201d and the \u201cjunkie\u201d habitus. Drugs Educ Prev Policy. 2015;22(3):248\u201354. https:\/\/doi.org\/10.3109\/09687637.2014.987219.","DOI":"10.3109\/09687637.2014.987219"},{"issue":"6","key":"510_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/DAR.12062\/SUPPINFO","volume":"32","author":"T Groshkova","year":"2013","unstructured":"Groshkova T, Metrebian N, Hallam C, Charles V, Martin A, Forzisi L, et al. Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the randomised injectable opiate treatment trial, the UK\u2019s first supervised injectable maintenance clinics. Drug Alcohol Rev. 2013;32(6):566\u201373. https:\/\/doi.org\/10.1111\/DAR.12062\/SUPPINFO.","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"510_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/J.JSAT.2013.10.004","volume":"46","author":"J Gryczynski","year":"2014","unstructured":"Gryczynski J, Mitchell SG, Jaffe JH, O\u2019Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356\u201361. https:\/\/doi.org\/10.1016\/J.JSAT.2013.10.004.","journal-title":"J Subst Abuse Treat"},{"key":"510_CR20","doi-asserted-by":"publisher","unstructured":"Hochheimer M, Unick GJ. Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race\/ethnicity, and gender in the United States. Addict Behav. 2022;124:107113. https:\/\/doi.org\/10.1016\/J.ADDBEH.2021.107113.","DOI":"10.1016\/J.ADDBEH.2021.107113"},{"key":"510_CR21","doi-asserted-by":"publisher","unstructured":"Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R. What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. J Subst Abuse Treat. 2022;108804. https:\/\/doi.org\/10.1016\/J.JSAT.2022.108804.","DOI":"10.1016\/J.JSAT.2022.108804"},{"issue":"1","key":"510_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/WCS.1203","volume":"4","author":"MC Hout","year":"2013","unstructured":"Hout MC, Papesh MH, Goldinger SD. Multidimensional scaling. Wiley Interdiscip Rev Cogn Sci. 2013;4(1):93\u2013103. https:\/\/doi.org\/10.1002\/WCS.1203.","journal-title":"Wiley Interdiscip Rev Cogn Sci"},{"issue":"9","key":"510_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"H-F Hsieh","year":"2005","unstructured":"Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"key":"510_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/J.JSAT.2018.07.008","volume":"93","author":"CW Jones","year":"2018","unstructured":"Jones CW, Christman Z, Smith CM, Safferman MR, Salzman M, Baston K, et al. Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abuse Treat. 2018;93:19\u201325. https:\/\/doi.org\/10.1016\/J.JSAT.2018.07.008.","journal-title":"J Subst Abuse Treat"},{"key":"510_CR25","unstructured":"Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, et al. Managing opioid use disorder in primary care: PEER simplified guideline. Canadian Family Physician.\u00a02019;65(5):321\u201330."},{"issue":"4","key":"510_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2149","volume":"166","author":"PT Korthuis","year":"2017","unstructured":"Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, et al. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2017;166(4):268\u201378. https:\/\/doi.org\/10.7326\/M16-2149.","journal-title":"Ann Intern Med"},{"key":"510_CR27","doi-asserted-by":"publisher","unstructured":"Kumar N, Oles W, Howell BA, et al. The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review. J Subst Abuse Treat. 2021;127:108367. https:\/\/doi.org\/10.1016\/J.JSAT.2021.108367.","DOI":"10.1016\/J.JSAT.2021.108367"},{"key":"510_CR28","doi-asserted-by":"publisher","unstructured":"Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS One. 2017;12(10). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0186315.","DOI":"10.1371\/JOURNAL.PONE.0186315"},{"issue":"12","key":"510_CR29","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","volume":"24","author":"J Ma","year":"2018","unstructured":"Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018;24(12):1868\u201383. https:\/\/doi.org\/10.1038\/s41380-018-0094-5.","journal-title":"Mol Psychiatry"},{"key":"510_CR30","doi-asserted-by":"publisher","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1). https:\/\/doi.org\/10.1186\/S13011-020-0253-Y.","DOI":"10.1186\/S13011-020-0253-Y"},{"key":"510_CR31","doi-asserted-by":"publisher","unstructured":"Mariolis T, Bosse J, Martin SA, et al. A systematic review of the effectiveness of buprenorphine for opioid use disorder compared to other treatments: implications for research and practice the impact of psychosocial treatment on medication treatment for opioid use disorder view project the effects of early adversity on chronic chronic HPA activity. View project a systematic review of the effectiveness of buprenorphine for opioid use disorder compared to other treatments: implications for research and practice. J Addict Res Ther. 2019;10(2). https:\/\/doi.org\/10.4172\/2155-6105.1000379.","DOI":"10.4172\/2155-6105.1000379"},{"key":"510_CR32","doi-asserted-by":"publisher","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3. https:\/\/doi.org\/10.1002\/14651858.CD002209.PUB2\/INFORMATION\/EN.","DOI":"10.1002\/14651858.CD002209.PUB2\/INFORMATION\/EN"},{"key":"510_CR33","doi-asserted-by":"publisher","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2). https:\/\/doi.org\/10.1002\/14651858.CD002207.PUB4.","DOI":"10.1002\/14651858.CD002207.PUB4"},{"key":"510_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/J.DRUGPO.2019.06.019","volume":"71","author":"K McLean","year":"2019","unstructured":"McLean K, Kavanaugh PR. \u201cThey\u2019re making it so hard for people to get help:\u201d motivations for non-prescribed buprenorphine use in a time of treatment expansion. Int J Drug Policy. 2019;71:118\u201324. https:\/\/doi.org\/10.1016\/J.DRUGPO.2019.06.019.","journal-title":"Int J Drug Policy"},{"key":"510_CR35","doi-asserted-by":"publisher","unstructured":"Mcnamara KF, Biondi BE, Hern\u00e1ndez-Ram\u00edrez RU, Taweh N, Grimshaw AA, Springer SA. A systematic review and Meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. 2021;8(8). https:\/\/doi.org\/10.1093\/OFID\/OFAB289.","DOI":"10.1093\/OFID\/OFAB289"},{"key":"510_CR36","doi-asserted-by":"publisher","unstructured":"Mitchell SG, Morioka R, Reisinger HS, et al. Redefining retention: Recovery from the patient\u2019s perspective. J Psychoactive Drugs. 2011;43(2):99\u2013107. https:\/\/doi.org\/10.1080\/02791072.2011.587392.","DOI":"10.1080\/02791072.2011.587392"},{"key":"510_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.DRUGALCDEP.2019.02.031","volume":"200","author":"JR Morgan","year":"2019","unstructured":"Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34\u20139. https:\/\/doi.org\/10.1016\/J.DRUGALCDEP.2019.02.031.","journal-title":"Drug Alcohol Depend"},{"key":"510_CR38","doi-asserted-by":"publisher","unstructured":"Nielsen S, Tse WC, Larance B. Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Cochrane Database Syst Rev. 2022;2022(9). https:\/\/doi.org\/10.1002\/14651858.CD011117.PUB3.","DOI":"10.1002\/14651858.CD011117.PUB3"},{"issue":"3","key":"510_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/S079096670001209X","volume":"28","author":"F O\u2019Reilly","year":"2011","unstructured":"O\u2019Reilly F, O\u2019Connell D, O\u2019Carroll A, Whitford DL, Long J. Sharing control: user involvement in general practice based methadone maintenance. Ir J Psychol Med. 2011;28(3):129\u201333. https:\/\/doi.org\/10.1017\/S079096670001209X.","journal-title":"Ir J Psychol Med"},{"issue":"10","key":"510_CR40","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/J.MAYOCP.2019.03.029\/ATTACHMENT\/381F99B4-6F42-4702-9F8C-16B6E0FF34D2\/MMC1.MP4","volume":"94","author":"TS Oesterle","year":"2019","unstructured":"Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. 2019;94(10):2072\u201386. https:\/\/doi.org\/10.1016\/J.MAYOCP.2019.03.029\/ATTACHMENT\/381F99B4-6F42-4702-9F8C-16B6E0FF34D2\/MMC1.MP4.","journal-title":"Mayo Clin Proc"},{"key":"510_CR41","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2015","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2015. Retrieved from https:\/\/www.r-project.org\/"},{"key":"510_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/PROM.S297699","volume":"13","author":"N Sanger","year":"2022","unstructured":"Sanger N, Panesar B, Dennis M, Rosic T, Rodrigues M, Lovell E, et al. The Inclusion of Patients\u2019 Reported Outcomes to Inform Treatment Effectiveness Measures in Opioid Use Disorder. A Systematic Review. Patient Relat Outcome Meas. 2022;13:113. https:\/\/doi.org\/10.2147\/PROM.S297699.","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"510_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000320576","volume":"17","author":"H St\u00f6ver","year":"2011","unstructured":"St\u00f6ver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17(1):44\u201354. https:\/\/doi.org\/10.1159\/000320576.","journal-title":"Eur Addict Res"},{"key":"510_CR44","doi-asserted-by":"publisher","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review.\u00a0J Addict Dis. 2016;35(1):22\u201335. https:\/\/doi.org\/10.1080\/10550887.2016.1100960.","DOI":"10.1080\/10550887.2016.1100960"},{"issue":"6","key":"510_CR45","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/INTQHC\/MZM042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International J Qual Health Care. 2007;19(6):349\u201357. https:\/\/doi.org\/10.1093\/INTQHC\/MZM042.","journal-title":"International J Qual Health Care"},{"key":"510_CR46","doi-asserted-by":"publisher","unstructured":"Trotter RT, Potter JM. Pile sorts, a cognitive anthropological model of drug and AIDS risks for Navajo teenagers: Assessment of a new evaluation tool. In: Drugs and Society. Vol 7. Taylor & Francis Group; 1993:23\u201339. https:\/\/doi.org\/10.1300\/J023v07n03_03.","DOI":"10.1300\/J023v07n03_03"},{"key":"510_CR47","doi-asserted-by":"publisher","unstructured":"Tysarowski M, Kazmi M, Barai R, Efobi R, Matassa D, Gordon E. Buprenorphine and methadone treatment is associated with less heart failure hospitalizations in patients with opioid use disorder. Circulation. 2020;142(Suppl_3). https:\/\/doi.org\/10.1161\/circ.142.suppl_3.16045.","DOI":"10.1161\/circ.142.suppl_3.16045"},{"issue":"2","key":"510_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"510_CR49","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2105\/AJPH.2019.305525","volume":"110","author":"LC Weinstein","year":"2020","unstructured":"Weinstein LC, Iqbal Q, Cunningham A, Debates R, Landistratis G, Doggett P, et al. Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017\u20132018. Am J Public Health. 2020;110(4):580\u20136. https:\/\/doi.org\/10.2105\/AJPH.2019.305525.","journal-title":"Am J Public Health"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-022-00510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-022-00510-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-022-00510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T05:04:41Z","timestamp":1673672681000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-022-00510-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1186\/s13011-022-00510-1","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"21 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Institutional Review Board at Thomas Jefferson University. All study participants were provided with information about the study and provided verbal informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}